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Chimpanzees and humans are closely related but diﬀer in many deadly human diseases and other characteristics in physiology,
anatomy, and pathology. In spite of decades of extensive research, crucial questions about the molecular mechanisms behind the
diﬀerences are yet to be understood. Here I report ExonVar, a novel computational pipeline for Exon-based human-chimpanzee
comparative Variant analysis. The objective is to comparatively analyze mutations speciﬁcally those that caused the frameshift and
nonsense mutations and to assess their scale and potential impacts on human-chimpanzee divergence. Genomewide analysis of
human and chimpanzee exons with ExonVar identiﬁed a number of species-speciﬁc, exon-disrupting mutations in chimpanzees
but much fewer in humans. Many were found on genes involved in important biological processes such as T cell lineage
development, the pathogenesis of inﬂammatory diseases, and antigen induced cell death. A “less-is-more” model was previously
established to illustrate the role of the gene inactivation and disruptions during human evolution. Here this analysis suggested
ad i ﬀerent model where the chimpanzee-speciﬁc exon-disrupting mutations may act as additional evolutionary force that drove
the human-chimpanzee divergence. Finally, the analysis revealed a number of sequencing errors in the chimpanzee and human
genome sequences and further illustrated that they could be corrected without resequencing.
Copyright © 2009 GongXin Yu. This is an open access article distributed under the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Chimpanzees (Pan troglodytes) and humans (Homosapiens)
are each other’s closest living relatives and yet the two
primates diﬀer enormously in many characteristics in phys-
iology, anatomy, and pathology [1]. Among the diﬀerences,
those in the frequency and severity to deadly human diseases
such as human immunodeﬁciency disease (HIV/AIDS),
Alzheimer’s disease, and Plasmodium falciparum malaria
are especially intriguing. In the case of HIV/AIDS, the
infections of HIV-1 rarely cause AIDS-like diseases in
chimpanzees. Protective strategies appear to have evolved
to pacify SIV/HIV [2]. Similarly, the great apes can be
infected with viral hepatitis B and C but do not progress to
chronic active hepatitis [3]. While the epithelial neoplasm
such as carcinomas of the breast, ovary, lung, stomach,
colon, pancreas, and prostate cause more than 20% of the
deaths in modern human populations, the occurrence rates
among the great apes are only ∼2%–4% or lower [4, 5].
Chimpanzees also appear to be immune to P. falciparum,
the most aggressive and acutely life-threatening malaria for
humans [6–8]. Finally, the great apes show no sign of the
complete pathological lesions of Alzheimer’s disease [9].
The beneﬁt of the comparative analysis of the closely
related species is obvious. Through such analyses, it is pos-
sible to detect key diﬀerences that propelled the chimpanzee-
human diﬀerentiation. The analysis thus could led to
an improved understanding of the molecular mechanisms
behind these diﬀerences and eventually to new therapies
[10]. For example, the HIV-infected chimpanzee diﬀers
from HIV-infected human individuals in the following
several aspects: (1) a low level of T cell activation and
bystander apoptosis in SIV/HIV-infected chimpanzees with
no evidence of immunodeﬁciency [11]; (2) a rapid estab-
lishment of an anti-inﬂammatory environment, which may
prevent the host from developing the aberrant chronic T cell2 Comparative and Functional Genomics
hyperactivation, a hallmark of progression to AIDS during
HIV-1 infection [12]; and (3) An absence of overt CD4+ T
cell loss. The nonpathogenic characteristics hence highlight
a protective role of down-regulated T cell activation and
the establishment of anti-inﬂammatory proﬁles early on
in immune responses. It is possible that such protection
allows the natural host to accept the virus that hence can
survive in a symbiotic state. Knowledge about the molecular
mechanismsofsuchprotectionwouldallowthedevelopment
of drugs as well as treatment plans that can imitate biological
processes that occur in the HIV-infected chimpanzees. The
consequence is to bring the disease under control [13].
The strategy could apply equally well to other diﬀerentially
evolved human diseases, for example, viral hepatitis B and
hepatitis C, should it prove successful. Chimpanzees display
a similar response to viral hepatitis B and C as they do to the
HIV/AIDS [14] where infected chimpanzees do not progress
to the chronic active hepatitis [3].
The availability of completely sequenced human
genomes [15, 16] and that of chimpanzees [1]w o u l d
have an immense impact on the comparative human-
chimpanzee analyses. For the ﬁrst time, nucleotide-by-
nucleotide comparisons can be performed at whole genome
levels. Already such analyses have resulted in some novel
observations and in-depth understandings. First, the two
closely related species diﬀer signiﬁcantly in chromosome
structures. Cheng et al. (2005) discovered diﬀerence in the
contents of segmental duplications [17]. About 33% of the
human duplications, including some human disease-causing
duplication, are not duplicated in the chimpanzees. Harris
et al. (2007) reconstructed ancestral states and the structural
evolution of the genomes and identiﬁed 130 human-speciﬁc
breakpoints due to rearrangements at an intermediate
scale (10 kilobases to 4 megabases) [18]. Recently, Kehrer-
Sawatzki and Cooper (2008) revealed a strong spatial
association between primate-speciﬁc breakpoints and
segmental duplications (SDs) [19].
Chimpanzees and humans were also found to diﬀer in
adaptive gene evolution. Clark et al. (2003) observed non-
neutral evolution from human-chimpanzee-mouse orthol-
ogous gene trios where signiﬁcantly diﬀerent patterns of
substitution were detected in the human lineage where
accelerated evolution was founded in several functional
classes, including olfaction and nuclear transport [10].
Marques-Bonet et al. found an association between chro-
mosomal rearrangements and genic evolution in human
and chimpanzee [20–22]. Genes located in the rearranged
chromosomes that diﬀerentiate the genomes of humans
and chimpanzees presented lower divergence than genes
elsewhere in the genome. These observations were further
supported by the chimpanzee sequencing project and the
subsequent human-chimpanzee comparative analysis [1].
The lineage-speciﬁc adaptive evolution was detected where
aﬀected genes diﬀered in the magnitude, regional variation,
and the strength of positive and negative selection. In spite
of the extensive research, many questions remain, especially
impacts of genetic mutations from recent human and chim-
panzee evolution. Here I reported a novel computational
platform named ExonVar for human-chimpanzee compara-
tive analysis with a new perspective: comparatively analyzing
mutations and their impacts on exon structures, speciﬁcally
those that cause frameshift and nonsense mutations. The
objective is to assess the scale and potential impacts of these
mutations on human-chimpanzee divergence.
The work was started because of the lack of appropriate
computationalproceduresforsuchanalysisalthoughafewof
comparative human-chimpanzee genome analysis methods
have been developed. Hahn and Lee are the ﬁrst group
to develop a procedure that can be applied for a large
scale analysis of ﬁrst frameshift [23] and then nonsense
mutations [24]. Their approach, relying on mRNA-genome
sequence alignments, has its limitation mainly because
of incomplete genome coverage of existing mRNA data
especially from chimpanzees. Puente et al. (2006) developed
the similar procedure but with a speciﬁc focus on cancer
genes [25]. Recently, Wetterbom et al. (2009) devised a
procedure for a genomewide analysis of chimpanzee genes
with premature termination codons [26]. In this approach,
exons downloaded from Ensembl and then translated.
Exons were subsequently concatenated and scanned for
premature termination codons. A main concern for this
approach is that the accuracies in the exon boundary
prediction will likely have a negative impact on the analysis.
Despite numerous developments of useful tools, predicting
exons and their precise exon–intron boundaries are still
a challenging task [27–29]. An incorrect prediction would
introduce incorrect open reading frames, thus false positive
results.
It was motivated by our early success in the development
of GenVar and by the observations that gene functional
modiﬁcation or inactivation plays a crucial role in human
genome evolution. GenVar is a computational pipeline to
comparatively analyze closely related bacterial genomes for
variant-pathogenesis association studies [30]. The pipeline
is unique in that it can analyze sequence variations such as
those that cause frameshift, nonsense and indel mutations at
the genome scale and within the context of closely related
bacterial species. From the analyses, mutations derived
from recent evolution can thus be identiﬁed, promising
a better understanding of the molecular basis underlying
diﬀerentially evolved phenotypes [31].
It was also motivated by the fact that genetic changes
can result in the acquisition of novel phenotypic traits,
manifested by small jaws and teeth, weakened jaw muscles,
decreased smell sensitivity, and reduced body hair. This
is what so called a “less-is-more” model [31, 32]. For
example, the human-speciﬁc 2-bp deletion in the coding
region of MYH16, a sarcomeric myosin gene, resulted
in a frameshift and was linked to the reduction of jaw
muscles that allowed humans to have bigger brains [33].
The single base-pair substitution introduced a premature
TGA termination codon in the human type I hair keratin
gene [34]. The resulting gene inactivation has been suggested
to evolve smooth, hairless skin in humans for enhanced
thermoregulation [35] and/or for reduction of parasite loads
[36]. Recently, multiple human-speciﬁc nonsense mutations
have been identiﬁed where abolished or modiﬁed functions
were predicted in the aﬀected genes [24].Comparative and Functional Genomics 3
It is thus hypothesized that functional modiﬁcation
or inactivation likely assumes greater roles in human-
chimpanzee diﬀerentiation. GenVar is a powerful tool to
test the hypothesis since it can assess the genome variations
at a global scale. GenVar, however, is a CPU-demanding
pipeline that presents a signiﬁcant challenge in the human-
chimpanzee genome study. First, there was an impractically
high computational cost and running time due to the
complexitiesofthehuman,chimpanzeeandothereukaryotic
genomes. The genomes are massive; human genome, for
example, consists of over three billion base pairs (bps) with
over 30,000 genes and 61,318 transcripts whereas average
bacterial genomes are about 3 million bps with around
3,000 genes/proteins. The genes from these genomes are
further more complicated than their bacterial counterparts.
They can reach up to millions of base pairs but only
tiny portions are actual coding sequences that are further
imbedded in vast arrays of non-coding DNA. Many genes
are alternatively spliced, forming multiple protein products
[37, 38]; moreover, duplication is a ubiquitous phenomenon
in humans and many other eukaryotic genomes and can
r e a c hal e v e lw i t ht h a tb a c t e r i a lg e n o m e sc a nb a r e l ym a t c h
[39, 40].
The complexities consequently result in genomic DNA
inputs with gigantic sizes and database inputs with hetero-
geneous protein components, thus slowing the GeneWise-
based analysis process and complicating result interpreta-
tions. This can be manifested by our earlier experiments.
A small-sized human chromosome (e.g., chromosome 21)
needs over three months of computational time in a Linux
node with a dual Intel processor. By contrast, bacteria, with
the same number of genes, need less than 24 hours [30].
Second, the result from the analysis was unreliable and inac-
curate when GeneWise was applied to align the interrupted,
mega-sized gene sequences (intron-exon structures) with
their homologous proteins. The unreliability was obvious:
approximately 24.48% of disrupted genes were revealed in
human chromosomes 21 when compared to homologous
proteins from humans, chimpanzees, and macaques but a
majority of the disruption mutations turned out to be false
positive when the alignments were manually examined.
ExonVar followed the same strategy as GenVar with
critical modiﬁcations to overcome the challenge. First, all
the analyses were performed on coding exons instead of
genes. The coding exons are much smaller, even smaller
than bacterial genes. With the divide and conquer strategy,
an immediate result is an improved performance. With the
same human chromosomes 21, the analysis can be ﬁnished
within 24 hours at the same Linux node. The modiﬁcations,
furthermore,comewithanincreasedaccuracyandsimpliﬁed
interpretation. All exon-disrupting mutations detected were
found in their corresponding trace sequences. Finally, the
human-chimpanzee analysis could be extended to include
the genomes of macaques and other mammals to deﬁne
lineage-speciﬁc sequence variants. With the computational
pipeline, human and chimpanzee exons were analyzed. This
paper presents a sample of total results to illustrate the
analysis procedure and to assess the scale and biological
impacts of the species-speciﬁc, exon-disrupting mutations.
2.MaterialsandMethods
2.1. Genome Data. Genome sequences of eight mammalian
species were downloaded from Ensembl database in (2007)
(ftp://ftp.ensembl.org/pub/). The downloaded data are
release-46 (Table 1). Each genome is comprised of proteins,
assembled chromosomes, and multiple MySQL ﬁles in the
database. All genomes have completely assembled chromo-
somes with some variations at the time when the data were
downloaded. For example, sequence data for humans consist
of22autosomalchromosomes,1mitochondrion,2sexchro-
mosomes,andthreeotherunassembledDNAfragments.The
MySQL ﬁles include several species-speciﬁc database tables
including gene.txt.table, gene stable id.txt.table, exon.txt
.table, exon transcript.txt.table, transcript.txt.table, transla-
tion stable id.txt.table, and translation.txt.table. The pur-
pose is to extract genomic information at the levels of genes,
exons, and proteins, and to deﬁne the exon-gene and exon-
protein relationships.
2.2. The ExonVar Implementation. ExonVar consists of three
steps: ﬁrst detect sequence mutations speciﬁcally those that
cause frameshift and nonsense in the coding sequences
are identiﬁed (i). Once identiﬁed, the occurrence patterns
of the mutations were deﬁned among the genomes of
humans, chimpanzees, macaque and ﬁve other mammals
(ii). Those that are speciﬁc to humans or chimpanzees were
subsequently validated (In Silico) to tag those that are caused
by sequencing errors (iii). Following sections give a detailed
description about the procedures.
(i) Develop the exon-based, variant discovering procedure.
The development followed the analysis procedure described
in GenVar but with a critical modiﬁcation [30]. Instead
of comparatively analyzing entire genes, which are hard to
handle because of massive size and complicated structures,
this procedure focuses solely on exons, the simplest and
smallest coding units in eukaryotic genomes. Brieﬂy, two
required inputs are ﬁrst established; one is Exon-based
genomic DNA input and another is the Exon-based Peptide
DataBase input (ExPepDB). The genomic DNA input was
deﬁned as an extended area of the predicted exons where
100 base pairs were added at both 3  and 5  ends. The
ExPepDB, established for each genomic DNA input, consists
of homologous peptide exons from all included genomes.
The peptide exons are the amino acid sequences of the
exons, translated by an in-house developed, Perl-based
program. The program basically performed BLAST analyses
against species-speciﬁc protein databases and subsequent
protein-exon sequence mapping. Note that data downloaded
from Ensembl have explicit speciﬁcations about protein-
exon relationships. The program takes the relationship as a
constraint. From that, amino acid sequences of any possible
overlapped coding exons can be unequivocally determined.
Once the two required inputs are established, they are
comparatively analyzed using GeneWise [42–44] to identify
sequence variations.
(ii) Identify lineage-speciﬁc exon-disrupting mutations.
To identify human- or chimpanzee-speciﬁc mutations, a
tree-based evolutionary scheme was devised based on a4 Comparative and Functional Genomics
Table 1: Eight assembled/partially assembled mammalian genomes.
Genomes Version Species symbol Commonname Assembled chromosomes Exon
Homo sapiens NCBI36.46 HS Human 1-22, X, Y, MT, c22-H2, c5-H2, c6-COX, c6-QBL 267971
Pan troglodytes CHIMP2.1.46 PT Chimpanzee 1, 2A, 2B, 3-22, X, Y, MT, nonchrom 236891
Rhesus macaque MMUL 1.46 RW Macaque 1-20, X, MT, nonchrom 242505
Mus musculus NCBIM36.46 MM Mouse 1-19, X, Y, MT, nonchrom, 229909
Rattus norvegicus RGSC3.4.46 RN Rat 1-20, X, MT, nonchrom 241761
Canis familiaris BROADD2.46 CF Dog 1-38, X, MT, nonchrom 211964
Bos taurus Btau 3.1.46 BT Cow 1-30, nonchrom 215534
Monodelphis domestica BROADO5.46 MD Opossum 1-8, X, MT, Un, nonchrom 244769
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Figure 1: The species tree-based analysis procedure is to deﬁne occurrence patterns of the exon-disrupting mutations. The tree is drawn
roughly based on a phylogenetic analysis of data from eight completely sequenced nuclear genomes [41]. Abbreviations of eight mammalian
species are listed as followings: HS = Homo sapiens,P T= Pan troglodytes,R M= Rhesus macaques,B T= Bos taurus,C F= Canis familiaris,
MD = Monodelphis domestica,M M= Mus musculus,a n dR N= Rattus norvegicus. Colored lines represent diﬀerent lineages: the red for
human-chimpanzee-macaque lineage; the green for dogs and cows; the blue for mouse-rat.
previously published mammalian species tree [41]. In this
scheme, macaques, cows, dogs, opossums, mice and rats,
which are closely related, but phylogenetically outside of
the chimpanzee and human clade, are used as out-groups
(Figure 1). Mutations that follow the species tree were
considered to be lineage-speciﬁc (panels I to V). Among
them, those that are speciﬁc to chimpanzees or humans (in
panel I and II) were deﬁned as chimpanzee- or human-
speciﬁc respectively.
(iii) Insilico validate the lineage-speciﬁc exon-disrupting
mutations. The ﬁrst step is to establish species-speciﬁc trace
databases for humans and chimpanzees. The trace data were
downloaded from NCBI Trace archive (ftp://ftp.ncbi.nih
.gov/pub/TraceDB/).Thehuman-speciﬁctracedatabasecov-
ered 188,150,586,226 base pairs (bp) of trace sequences
from the diploid genome sequences of Dr. Craig J. Venter,
Dr. James D. Watson, and other human sequencing projects,
and has a total coverage of 58X based on the humanComparative and Functional Genomics 5
genome size of 3,253,037,807bps. The chimpanzee-trace
database is much smaller, which includes 43,176,085,998bp
trace sequences from Pan troglodytes,ac o v e r a g eo fm e r e l y
15X. The database was extended to include 321,835,
223bp trace sequences from pongo pygmaeus (sequenc-
ing project) and 15,420,096,318bp trace sequences from
pongo pygmaeus abelii (sequencing project). The extension
led to a 5.4X increase in the genome coverage (see results and
discussion for reasoning to include Pongo sequences).
The second step is to select query sequences. The objec-
tive is to validate the frame-disrupting mutations in target
exons. The query sequences are the orthologous exons from
the closest related genome, for example, exons in humans
to those in chimpanzees or vice verse. The queries are then
used to search the species-speciﬁc trace DNA database. Trace
sequenceswithatleasta95%sequenceidentityareextracted.
They were named candidate trace sequences to represent
those that were sequenced directly from the chromosomal
regions where the disrupted exons are detected. The can-
didate trace sequences, along with query-speciﬁc ExPepDB,
are comparatively analyzed with GeneWise. The GeneWise
alignments are evaluated with a set of predetermined rules.
The assumption underlying the rules is that mutations
derived from evolution (accepted mutations) will lead to the
consistent occurrence of the variations among the candidate
trace sequences whereas sequencing errors to randomness
if ever occurred. Speciﬁcally, the rules say that for a given
query,
(i) there will be at least n candidate trace sequences
that have a coverage on the regions where the exon-
disrupting mutations occur where n ≥ 2a n d
(ii) among the n candidate trace sequences at least m
display exactly identical mutations in types and
positions where m ≥ 2;
(iii) none of the candidate trace sequences show a com-
plete alignment with their orthologous sequences
where no disruptions were displayed.
If all statements described above are evaluated as true, the
status of the mutations will be considered as true and
recognized as accepted mutations. Otherwise, the status of
the mutations will be recognized as either false (statement
I is true, but both II and III are false) or undetermined
(statement I is false or both statement I and II are true but
III is false).
2.3. Program Implementation. All implementations were
based on the PERL script language. Wise2 was down-
loaded from EMBL-EBI (http://www.sanger.ac.uk/Software/
Wise2/). ExonVar is available to noncommercial users upon
request.
3. Results andDiscussion
3.1. Comparative Analysis of the Exon-Disrupting Mutations.
Following the procedure of ExonVar, all 504,862 predicted
human and chimpanzee exons were analyzed. The analysis
revealed signiﬁcant diﬀerences between chimpanzees and
humans.Theﬁrstisthenumberofthedisruptedexons:there
are 1,931 disrupted exons in humans while that number is
3,742, approximately doubled in chimpanzees. The second
is the occurrence patterns of the exon-disrupting mutations,
which describes how the mutations are distributed among
the genomes. In the human genome, only a small portion of
themutationsareinvolvedincross-speciesvariationbetween
humans and chimpanzees. In chromosome X, for example,
the number is 7.3% (eight out of 109 of the disrupted exons).
Examples include HUMAN 1 851437 (solute carrier family
26, member 9 isoform A), HUMAN 1 837766 (calcium
activated chloride channel 3 precursor) (Table 2). The exon-
disrupting mutations are human-speciﬁc where they were
detected in humans only. A majority of the disrupting
mutations are, however, not species-speciﬁc. For instance,
the exon-disrupting mutations in HUMAN X 817906 (can-
cer/testis antigen 2) were detected by another human exon;
that in HUMAN X 806072 (intestinal protein OCI-5) by an
exon from the dog genome, and that in HUMAN X 815259
(green-sensitive opsin) by an exon from the macaque
genome.
Onthecontrary,amajorityoftheexon-disrupting muta-
tions in chimpanzees were involved in human homologues,
for example, 59.7% (114 out of 193 disrupted exons) in
chromosomeX.Amongtheexons,CHIMP X 104156(ADP-
ribosylation factor-like protein 13A), CHIMP X 99308
(Cylicin-1), CHIMP X 146199 (AF4/FMR2 family member
2), CHIMP X 144941 and CHIMP X 144913 (melanoma-
associated antigen C3) have disrupted reading frames when
compared to their human and macaque orthologs, thus
speciﬁc to chimpanzees. A similar phenomenon was found
in other chromosomes (data not shown). Note that the exon
names were designed for clarity and consistency where exon
identiﬁcation numbers from Ensembl database, for example,
142174 in CHIMP X 142174, were used as bases with the
preﬁxes of species abbreviations (CHIMP) and chromosome
numbers (X).
3.2. Validation of the Species-Speciﬁc Exon-Disrupting Muta-
tions. The exon-disrupting mutations can come from
either sequence artifacts or accepted mutations [30].
With chimpanzee-speciﬁc trace databases, a total of 189
chimpanzee-speciﬁc frame-disrupted exons were examined
with the predetermined rules. Case studies are represented
here to illustrate the rules and their applications.
Case 1. One chimpanzee-speciﬁc frameshift mutation was
detected in CHIMP X 139912 (cancer/testis antigen CT45).
A total of 62 candidate trace sequences were extracted
from the chimpanzee-speciﬁc trace database. An identical
frameshift was revealed in all 62 sequences (Figure 2). Rules
applied here are the following: (1) multiple candidate trace
sequences were identiﬁed; (2) the exact same mutations
in at least two seed sequences were observed; (3) no
candidate trace sequences showed complete (undisrupted)
open reading frame. The conclusion is that the frameshift
mutation can be accepted as an adapted mutation derived
from the recent human-chimpanzee evolution.6 Comparative and Functional Genomics
Table 2: The occurrence patterns of exon-disrupting mutations on chromosome X of humans and chimpanzees.
Frameshift Premature stop codon Subject peptide exon Alignment score Function annotation
EXON ID: HUMAN X 792407 Testis-expressedsequence 13A protein
104351239 - CHIMP X 110562 715.92 Testis-expressed sequence 13A protein
-- H U M A N X 792407 607.24 Testis-expressed sequence 13A protein
-- C H I M P X 110628 435.54 Testis-expressed sequence 13A protein
- - MONK X 10782 288.8 Testis-expressed sequence 13B protein
-- D O G X 198644 272.73 \N
HUMAN X 806072 Glypican-3 precursor(IntestinalproteinOCI-5)
132662038 - DOG X 194924 136.67 Glypican-3 precursor
-- H U M A N X 806072 117.76 Glypican-3 precursor
- - MONK X 12252 117.76 Glypican-3 precursor
-- M O U S E X 2142643 116.89 Glypican-3 precursor
HUMAN X 817906 Cancer/testisantigen 1B
153468119 - HUMAN X 818108 231.77 Cancer/testis antigen 2
-- H U M A N X 817906 216.52 Cancer/testis antigen 1B
-- H U M A N X 817908 117.27 Cancer/testis antigen 1B
- - MONK X 13842 102.91 \N
- - MONK X 13845 84.38 \N
-- H U M A N X 818110 78.11 Cancer/testis antigen 2
-- C H I M P X 160765 78.02 Cancer/testis antigen 2
-- C H I M P X 160692 52.31 \N
HUMAN X 815259 Green-sensitiveopsin
- 153149508 MONK X 13549 298.36 \N
-- H U M A N X 815212 223.34 Green-sensitive opsin
-- H U M A N X 815259 223.34 Green-sensitive opsin
-- C H I M P X 157000 204.73 Red-sensitive opsin
-- H U M A N X 815154 204.73 Red-sensitive opsin
-- D O G X 197028 201.64 Red-sensitive opsin
-- R A T X 186855 200.53 opsin 1 (cone pigments)
- - OPOSSUM X 8729 199.61 \N
HUMAN X 781680 Translationally-controlledtumor protein(TCTP)(p23)
- - CHIMP X 92139 367.27 TPT1-like protein
-- H U M A N X 781680 367.27 TPT1-like protein
71297119 & 71297149 - MONK 1 81482 343.44 Translationally-controlled tumor protein (TCTP)
(p23)
71297119 & 71297149 - MONK 9 138306 335.33 \N
71297119 & 71297149 - MOUSE 6 2214409 326.93 Tumor protein, translationally-controlled 1
71297119 & 71297149 - MOUSE 9 2157034 323.69 \N
71297119 & 71297149 - RAT 1 18606 319.31 \N
- - OPOSSUM 1 184539 318.51 \N
- - OPOSSUM 4 115959 302.14 \N
71297122 & 71297149 - RAT 16 40873 298.6 \N
71297119 & 71297149 - RAT 7 212305 293.94 \NComparative and Functional Genomics 7
Table 2: Continued.
Frameshift Premature stop codon Subject peptide exon Alignment score Function annotation
HUMAN X 805870 Heparan-sulfate6-O-sulfotransferase2 (EC2.8.2.-) (HS6ST-2)
131920284 - MONK X 12231 316.46 Heparan-sulfate 6-O-sulfotransferase 2
131920284 - COW Un 11290 273.56 \N
131920284 - DOG X 154771 268.61 \N
131920284 - MOUSE X 2142311 125.07 Heparan sulfate 6-O-sulfotransferase 2
131920284 - RAT X 171447 125.07 \N
-- H U M A N X 805870 72.68 Heparan-sulfate 6-O-sulfotransferase 2
-- C H I M P X 136642 68.81 Heparan-sulfate 6-O-sulfotransferase 2
HUMAN 1 851437 solute carrier family 26, member 9 isoformA
204150951 - CHIMP 1 235519 351.23 Solute carrier family 26, member 9 isoform A
204150951 - MONK 1 76747 337.22 Solute carrier family 26, member 9 isoform A
-- H U M A N 1 851437 252.06 Solute carrier family 26, member 9 isoform A
-- H U M A N 1 851439 252.06 Solute carrier family 26, member 9 isoform A
HUMAN 1 837766 calcium activated chloridechannel 3 precursor
- 86881166 CHIMP 1 224547 183.12 Calcium activated chloride channel 3 precursor
-- H U M A N 1 837766 157.82 Calcium activated chloride channel 3 precursor
- 86881166 COW 3 170345 139.02 Calcium activated chloride channel 3 precursor
- 86881166 COW 3 170045 138.65 Calcium activated chloride channel 3 precursor
- 86881166 DOG 6 162589 128.97 Calcium activated chloride channel 3 precursor
- 86881166 MOUSE 3 2282090 123.94 Calcium activated chloride channel 3 precursor
- 86881166 RAT 2 220515 118.93 Calcium activated chloride channel 3 precursor
- 86881166 MONK 1 36555 103.72 Calcium activated chloride channel 3 precursor
HUMAN X 785548 Putative P2Y purinoceptor10 (P2Y10) (P2Y-likereceptor)
78227761 - RAT X 146932 618.82 \N
78227761 - MOUSE X 2200474 617.25 RIKEN cDNA A630033H20 gene [
-- H U M A N X 785548 579.93 \N
- - CHIMP X 98456 563.37 \N
78227761 - OPOSSUM X 50171 459.83 \N
78227761 - MONK X 9587 432.12 Putative P2Y purinoceptor 10 (P2Y10)
78227761 - HUMAN X 785541 431.7 Putative P2Y purinoceptor 10 (P2Y10)
78227761 - DOG X 165474 419.31 \N
78227761 - COW Un 11583 417.2 purinergic receptor P2Y, G—protein coupled, 10
CHIMP X 29616 Putativeataxin-3-like protein (Machado-Josephdisease protein 1-like)
- - CHIMP X 29616 432.13 Putative ataxin-3-like protein
- 13263802 HUMAN X 705429 423.98 Putative ataxin-3-like protein
- 13263802 HUMAN X 705430 394.12 Putative ataxin-3-like protein
- 13263802 MONK X 3550 376.14 Putative ataxin-3-like protein
CHIMP X 144931 Melanoma-associated antigen C3 (MAGE-C3antigen)
141392714 - HUMAN X 809214 555.35 Melanoma-associated antigen C3
141392714 - HUMAN X 809208 365.01 Melanoma-associated antigen C3
-- C H I M P X 144931 125.45 Melanoma-associated antigen C3
-- C O W 15 185185 50.28 \N8 Comparative and Functional Genomics
Table 2: Continued.
Frameshift Prematurestopcodon Subject peptide exon Alignment score Function annotation
CHIMP X 146199 AF4/FMR2family member 2(FragileX mental retardationprotein 2homolog)
148435573 - HUMAN X 809667 867.67 AF4/FMR2 family member 2
148435573 - MONK X 12858 854.06 AF4/FMR2 family member 2
-- CHIMP X 146586 844 AF4/FMR2 family member 2
-- CHIMP X 146199 840.35 AF4/FMR2 family member 2
148435573 - DOG X 165267 735.92 AF4/FMR2 family member 2
148435573 - MOUSE X 2153947 701.72 AF4/FMR2 family, member 2
148435573 - RAT X 179540 701.09 \N
148435573 - COW X 46124 690.64 AF4/FMR2 family member 2
148435570 - DANIO 14 239638 274.31 AF4/FMR2 family member 2
CHIMP X 99308 Cylicin-1(CylicinI) (Multiple-bandpolypeptide I)
83230590 - HUMAN X 786289 1347.4 Cylicin-1 (Cylicin I)
83230590 - MONK X 9728 1143.6 Cylicin-1 (Cylicin I)
-- CHIMP X 99308 1123.9
Pan troglodytes cylicin, basic
protein of sperm head
cytoskeleton 1 (CYLC1), mRNA
-- MONK X 9731 827.18 Cylicin-1 (Cylicin I)
-- MONK X 9741 375.4 Cylicin-1 (Cylicin I)
-- MONK X 9742 316.01 Cylicin-1 (Cylicin I)
83230593 - DOG X 87481 305.14 Cylicin-1 (Cylicin I)
-- DOG X 87432 214.85 Cylicin-1 (Cylicin I)
-- RAT X 149412 164.28 \N
CHIMP X 142174 HIVTat-speciﬁc factor 1 (Tat-SF1)
135897343 - MONK X 12551 108.9 HIV Tat-speciﬁc factor 1 (Tat-SF1)
135897343 & 135897388 & 135897418 - HUMAN X 807829 106.55 HIV Tat-speciﬁc factor 1 (Tat-SF1)
135897343 - DOG X 183603 94.43
135897343 - COW X 29917 91.31 Hypothetical protein (Fragment)
135897343 - RAT X 174621 85.76 HIV TAT speciﬁc factor 1
135897343 - COW 12 95371 82.45 \N
135897343 - MOUSE X 2148052 77.47 HIV TAT speciﬁc factor 1
-- CHIMP X 142174 61.13 HIV Tat-speciﬁc factor 1 (Tat-SF1)
Note: Numbers under the columns of frameshifts and premature stop codons are the chromosomal positions of the sequence mutations. “\N” presents no
annotation available from Ensemble database.
Case 2. Four chimpanzee-speciﬁc frameshift mutations were
detected in CHIMP X 142174 (HIV Tat-speciﬁc factor (1)
eight trace sequences were identiﬁed from the chimpanzee-
speciﬁc trace database and only one was revealed to have
the frameshift mutations. Some of the sequences had
perfect alignments with its human and macaque orthologs
(Figure 3). Rules applied here are the following: (1) Iden-
tiﬁed multiple candidate trace sequences; (2) observed
the frameshift mutation in one candidate trace sequence
only, which I believed to be the seed sequence that was
used for the original genome assembly; and (3) detected
undisrupted open reading frames from multiple candidate
trace sequences including one from Pongo pygmaeus abelii.
Theconclusionisthattheframeshiftmutationswererejected
andthedisruptedexonwaspredictedtobeduetosequencing
artifacts.
Exon-disrupting mutations were also validated in the
genes or homologues of cancer/testis antigen CT45-3,
melanoma-associated antigen C3, the inhibitor of growth
family, member 1, protocadherin-11 X-linked precursor,
potassium channel tetramerisation domain containing 9-
like, testis-expressed sequence 13A protein, tumor necrosis
factor receptor superfamily member 18 precursor, heat-
shock protein beta-7, eyes absent homolog 3, (EC 3.1.3.48),Comparative and Functional Genomics 9
HUMAN_X_807093 1 LMTGHAI PPSQLDSQIDDFTGFS KDGMMQKPGSNAPVGGNVTSNFSGDD
LMTG AIPPSQLDSQIDDF KD M QK GSNAPVGG +TSNFSGDD
LMTGDAIPPSQLDSQIDDF!- - - KDRMRQKSGSNAPVGGIMTSNFSGDD
gnl|ti|12291657 139 c a a g g g a c c a c t g t c a g g t 2 a g a a a c a t g a a g c g g g a a a a a t t g g g
ttcgactccgatacataat aagtgaacggacctggttcgatcgaa
tgaatttaccagttgttcc atggggattctatgaacgcctctatc
HUMAN_X_807093 1 LMTGHAI PPSQLDSQIDDFTGFSKDGMMQKPGSNAPVGGNVTSNFSGDD
LM TG AIPPSQ LDSQIDDF KD M Q K GSNAPVGG +TSNFSGDD
LMTGDAI PPS QLDS QI DDF ! - - - KDRMRQKSGSNAPVGGIMTSNFSGDD
gnl|ti|12785267 309 c a a g g g a c c a c t g t c a g g t 2 a g a a a c a t g a a g c g g g aaaaattggg
ttcgactccgatacataat aagtgaacggacctggttcgatcgaa
tgaatttaccagttgttcc atggggattctatgaacgcctctatc
HUMAN_X_807093 1 LMTGHAI PPSQLDSQIDDFTGFSKDGMMQKPGSNAPVGGNVTSNFSGDD
LM TG AIPPSQ LD SQ ID DF KD M Q K G SN APV G G +TSNFSG D D
LMTGDA I PPSQLDSQIDD F! - - - KDRMRQKSGSNAPVGGIMTSNF SGDD
gnl|ti|12291379 249 c a a g g g a c c a c t g t c a g g t2 a g a a a c a t g a a g c g g g a a a a a t t g g g
ttcgactccgatacataat aagtgaacg gacctggttcgatcgaa
tgaatttaccagttgttcc atggggattctatgaacgcctctatc
HUMAN_X_807093 50 LECRGIAS SPKSQQE INADIKCQVVKE IRCLGR
LEC R I PKSQ +EIN A DIK C Q +V KEIRC+ G +
LECREI VLFPKSQEEINADI KCQLVKEI RCI GQ
gnl|ti|12291379 386 c g t a g a g c t c a a c g g a a g g a a t c t g a g a c t ag c
taggattttcagaaatacatagattaatggtga
aacaaacttcacaaattttaataaggacactaa
CHIMP_X_139912 1 KDRMRQKSGSNAPVGGIMTSNFSGDDLECRE IVLFPKSQEE INADIKCQ
KDRMRQKSGSNAPVGGIMTSNFSGDDLECREIVLFPKSQEEINADIKCQ
KDRMRQKSGSNAPVGGIMTSNFSGDDLECRE IVLFPKSQEE INADIKCQ
gnl|ti|12785267 368 a g a a a c a t g a a g c g g g a a a a a t t g g g c g t a g a g c t c a a c g g a a g g a a t c
aagtgaacggacctggttcgatcgaataggattttcagaaatacataga
atggggattctatgaacgcctctatcaacaaacttcacaaattttaata
CHIMP_X_139912 50 LVKE IRCIGQ
LVKEIRCIGQ
LVKEIRCIGQ
gnl|ti|12785267 515 t g a g a c t a g c
ttaatggtga
aggacactaa
II
I
Figure 2: Validation of the chimpanzee-speciﬁc frameshift mutation in CHIMP X 139912 (cancer/testis antigen CT45): (I) sequence
alignments between the human orthologous exon and three candidate seed sequences from chimpanzee-speciﬁc trace database (gn1 |ti|
1278267, gn1 |ti| 12291279, gn1 |ti| 12291657). (II) sequence alignment between the chimpanzee exon and one of its candidate trace
sequences. “!” represents frameshift mutations.
neuroblastoma breakpoint family, member 11, tropomyosin
alpha-3 chain (Tropomyosin-3), voltage-dependent R-type
calcium channel subunit alpha-1E, ADP-ribosylation factor-
like protein 13A, SOX-13 protein (Type 1 diabetes autoanti-
gen ICA12) (Islet cell antigen 12) (Table 3) and 36 other
chimpanzee genes (data not shown).
Including trace sequences from two Pongo sequencing
projects increased the genome coverage and enhanced the
capability in the validation of the exon-disrupting mutations
in the chimpanzee genome. For example, two frameshift
mutations were found in CHIMP 1 235104, an exon of
SOX-13 protein gene but only one chimpanzee candi-
date trace sequence was extracted from the chimpanzee-
speciﬁc trace database. Fortunately two other candidate
trace sequences were identiﬁed from the Pongo pygmaeus
abelii trace database. All three candidates bear the same
frameshift mutation, leading us to consider the frameshift
as an accepted mutation. In CHIMP 1 178077, an exon for
heat-shock protein beta-7, one homologous trace sequence
from Pongo pygmaeus abelii was identiﬁed and found to
share a nonsense mutation with three other chimpanzee
trace sequences. A similar phenomenon was observed in
many other exon-disrupting mutations in chimpanzee exons
such as CHIMP 1 229134, an exon for tropomyosin alpha-
3 chain (Tropomyosin-3), and CHIMP X 91363, an exon
for inhibitor of growth protein 1 homolog. On the other10 Comparative and Functional Genomics
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II
III
HUMAN_X_807820 5 NLDGNDEFDEQLRMQELYGDGKDGDTQTDAGGEPDSLGQQPTDTPYEWDLDKKAWFP
+ LDGNDEF DEQ RMQELYGDGKDGDTQ DAGGEPDS LG QPTDTPYEW LDKKAWFP
HLDGNDEF DEQ! RMQELYGDGKDGDTQ! DAGGEPDS LG! QPTDTPYEW! LDKKAWFP
CHIMP_430358433 −
−
−
967 ctggaggtggc2cacgttgggagggac4gggggcgtcg2ccagactgt2cgaagttc
atagaaataaa gtaatagagaagaca acggacactg accaccaag taaacgtc
cgtgctgttgg agaagcaccgttccg ttcaacttcc gggctccgg gcagtgcc
HUMAN_X_807820 12 FDEQLRMQELYGDGKDGDTQTDAGGEPDSLGQQPTDTPYEWDLDKKAWFP
FDEQLRMQELYGDGKDGDTQTDAGGEPDSLGQQPTDTPYEWDLDKKAWFP
FDEQLRMQELYGDGKDGDTQTDAGGE PDSLGQQPTDTPYEWDLDKKAWFP
CHIMP_204290505 300 t ggc t c ac gt t gggagggac agggggc gt c gc c c agac t gt gc gaa gt t c
taaatgtaatagagaagacacacggacactgaaccaccaagataaacgtc
ttgggagaagcaccgttccgcttcaacttccggggctccggcgcagtgcc
HUMAN_X_807820 1 MSGTNLDGNDEFDEQLRMQELYGDGKDGDTQTDAGGEPDSLGQQPTDTPYEWDLDKKAWFP
MSGTNLDGNDEFDEQLRMQELYGDGKDGDTQTDAGGEPDSLGQQPTDTPYEWDLDKKAWFP
MSGTNLDGNDEFDEQLRMQELYGDGKDGDTQTDAGGEPDSLGQQPTDTPYEWDLDKKAWFP
CHIMP_932757211 388 aa ga at ggaggt ggc t c a c gt t ggga ggga c a gggggc gt c gc c c a ga c t gt g cga agt t c
tggcatagaaataaatgtaatagagaagacacacggacactgaaccaccaagataaacgtc
gccccgtgctgttgggagaagcaccgttccgcttcaacttccggggctccggcgcagtgcc
Figure 3: The validation of the chimpanzee-speciﬁc frameshift mutations in CHIMP X 142174 (HIV Tat-speciﬁc factor (1): sequence
alignments between the human orthologous exon and the candidate trace sequences from chimpanzee (I) and (II) and that from pongo
pygmaeus abelii (III).
hand, diﬀerences were also observed between chimpanzees
andpongos.Forinstance,aframeshiftmutationwasdetected
in14chimpanzee candidatetracesequencesbutnot inanyof
the ﬁve pongo candidates. The observation is not surprising
considering an approximate 13.04Mya to 17.74Mya diﬀer-
entiation time between Pan troglodytes and Pongo pygmaeus,
a more distant relationship than between Pan troglodytes and
Homo sapiens (a range of 5.65 Mya to 8.27 Mya) (http://www
.timetree.org/)[ 45].
In summary, the analysis found an apparent asymme-
try where more species-speciﬁc, exon-disrupting mutations
were detected in chimpanzees than those in humans. One
of the possible assumptions is that there is a bias towards
detecting exons that are intact in humans because of more
careful/complete annotations. Indeed, errors in annotations
were detected in CHIMP X 142174 and many other chim-
panzee exons. We expected, however, such annotation errors
wouldhavelimitedimpactsontheasymmetrybecauseofour
experimental design where all exons were extended by 100
base pairs at both end of the exons and then comparatively
analyzed. The results were further Insilico validated.
3.3. The Structural Impacts. The lineage-speciﬁc exon-
disrupting mutations were detected on many coding exons
from the chimpanzee genome. Several examples were pre-
sented here to illustrate their potential structural and
biological impacts, ﬁrst through structure analysis of the
aﬀected genes and their resulting proteins, and then via
the analyses of biological functions of the genes. Indeed, a
combining eﬀect of nonsense, frameshift, and exon missing
mutations (data not shown) had completely reshaped the
structure of the chimpanzee melanoma-associated gene C3
(Figure 4). Its exons were fractured where two human exons
were split into a total of ﬁve chimpanzee ones (Figure 4(I)).
Furthermore, the resulting protein sequence lost one of two
functional MAGE domains (Figure 4(II)). Similar impacts
were observed on melanoma-associated gene C2, SOX-13
protein(Type1diabetesautoantigenICA12),tumornecrosis
factor receptor superfamily member 18 precursor and many
other genes where the overall structures of genes and their
protein products were aﬀected.
3.4. Functional Impacts. Genes with the species-speciﬁc
exon-disrupting mutations appear to be involved in some
critical physiological and biological processes. In chim-
panzees, for example, aﬀected genes included those encoding
a series of the melanoma-associated antigens, for example,
MAGE-C1 antigen, MAGE-3, MAGE-C2 and MAGE-1 anti-
gen in addition to MAGE-C3 described above. Additional
aﬀected genes include those for the inhibitor of the growth
family, member 1 (ING1), the testis-expressed sequence
13A protein, neuroblastoma breakpoint family, member
11, the tumor necrosis factor receptor superfamily mem-
ber 18 precursor (TNFSF18), SOX-13 protein, heat-shock
protein beta-7 (HSPB7), Eya3 and protocadherin-11 X-
linked precursor (PCDH11X). These are genes/homologues
with crucial roles in cell diﬀerentiations and develop-
ments.
The melanoma-associated genes are unique in that they
are strictly tumor- and testis-speciﬁc and furthermore, their
protein products can be recognized by autologous cytolytic
T lymphocytes in many human tumors [47]. The inhibitor
of the growth family, member 1 (ING1) is a breast cancer
suppressor gene [48]. The acute expression of transfected
constructs encoding ING1 inhibited cell growth while
chronic expression of ING1 antisense constructs promotedComparative and Functional Genomics 11
Table 3: Insilico validation of exon-disrupting mutations.
FR PM Subject Score Function description
CHIMP X 139912: PREDICTED:Pan troglodytes similarto Cancer/testisantigen CT45-3
135199011 - MONK X 12447 197.76 \N
-- C H I M P X 139912 159.41 Pan troglodytes similar to Cancer/testis antigen CT45-3
135199011 - HUMAN X 807093 140.8 Cancer/testis antigen CT45-4 (CT45-4)
135199011 - HUMAN X 806975 138.76 Cancer/testis antigen CT45
135199011 - HUMAN X 807082 138.76 Cancer/testis antigen CT45-4 (CT45-4)
135199011 - HUMAN X 807113 138.76 Cancer/testis antigen CT45-6 (CT45-6)
135199011 - HUMAN X 806962 137.58 Cancer/testis antigen CT45-1 (CT45-1)
135199011 - HUMAN X 806970 137.58 Cancer/testis antigen CT45
135199011 - MONK X 12441 136.48 \N
135199011 - CHIMP X 140002 132.22 \N
CHIMP X 144913: Melanoma-associated antigen C3
141390311 141390248 MONK X 12774 153.22 \N
141390314 141390248 HUMAN X 809204 118.25 Melanoma-associated antigen C3
-- C H I M P X 144913 104.42 Melanoma-associated antigen C3
CHIMP X 144941: Melanoma-associated antigen C3
141392714 141393341 - HUMAN X 809214 811.08 Melanoma-associated antigen C3
141392714 - HUMAN X 809208 504.96 Melanoma-associated antigen C3
141392720 - MONK X 12788 498.06 Melanoma-associated antigen C2
141392720 - HUMAN X 809255 489.78 Melanoma-associated antigen C2
-- C H I M P X 144941 415.82 Melanoma-associated antigen C3
Chimp x 91363: Homologof Inhibitorof growth protein1
70808615 70808558 70808522 70808408 MONK 17 129198 197.85 Inhibitor of growth protein 1
70808615 70808558 70808522 70808408 MONK 17 129202 197.85 Inhibitor of growth protein 1
70808615 70808558 70808522 70808408 MONK 17 129209 197.85 Inhibitor of growth protein 1
70808615 70808558 70808522 70808408 CHIMP 13 65452 196.75 Inhibitor of growth protein 1
70808615 70808558 70808522 70808408 HUMAN 13 720109 196.75 Inhibitor of growth protein 1
70808615 70808558 70808522 70808408 HUMAN 13 720111 196.75 Inhibitor of growth protein 1
70808615 70808558 70808522 70808408 HUMAN 13 720113 196.75 Inhibitor of growth protein 1
70808615 70808558 70808522 70808408 HUMAN 13 720115 196.75 Inhibitor of growth protein 1
70808548 70808521 70808407 RAT 16 143085 188.7 Inhibitor of growth family, member 1
70808548 70808521 70808407 DOG 22 9324 186.9 \N
70808548 70808521 70808407 MOUSE 8 2111806 185.9 Inhibitor of growth family, member 1
70808548 70808521 70808407 OPOSSUM 7 30919 185.56 Inhibitor of growth protein 1
70808548 70808521 70808407 COW 12 131559 181.68 Inhibitor of growth protein 1
-- C H I M P X 91363 133.05 \N
- 70808403 DANIO 9 335418 127.32 Hypothetical protein
- 70808403 DANIO 9 335470 127.32 Hypothetical protein
- 70808403 CHIMP 4 171949 112.69 Inhibitor of growth protein 2
- 70808403 COW 27 26326 112.69 \N
- 70808403 DOG 16 29019 112.69 \N
- 70808403 HUMAN 4 708541 112.69 Inhibitor of growth protein 2
- 70808403 MONK 5 172003 112.69 Inhibitor of growth family, member 1-like
- 70808403 OPOSSUM 5 33934 112.69 Inhibitor of growth protein 2
- 70808403 MOUSE 8 2166090 111.86 Inhibitor of growth family, member 2
- 70808403 RAT 16 84084 110.51 \N
- 70808403 DANIO 1 359897 109.25 Hypothetical protein12 Comparative and Functional Genomics
Table 3: Continued.
FR PM Subject Score Function description
CHIMP X 101234: Protocadherin-11X-linkedprecursor
-- C H I M P X 101234 516.68 Protocadherin-11 X-linked precursor
91237579 - HUMAN Y 591033 515.03 Protocadherin-11 Y-linked precursor
-- H U M A N X 787233 509.39 Protocadherin-11 X-linked precursor
-- C H I M P X 101543 479.57 Protocadherin-11 X-linked precursor
-- C H I M P X 101362 473.55 Protocadherin-11 X-linked precursor
CHIMP X 110683: Potassiumchannel tetramerisationdomain containing9-like
104937007 104936803 104936929 HUMAN 9 756669 340.71 \N
104937007 104936803 104936929 CHIMP 9 89777 334.23 \N
104937147 104936946 104937072 HUMAN 8 631149 238.77 \N
- 104936946 HUMAN X 792440 182.69 Potassium channel tetramerisation domain containing
9-like
- 104936946 HUMAN X 792443 180.93 Potassium channel tetramerisation domain containing
9-like
-- C H I M P X 110683 93.45 Potassium channel tetramerisation domain containing
9-like
CHIMP X 110628: Testis-expressedsequence 13A protein
104742590 - HUMAN X 792407 564.62 Testis-expressed sequence 13A protein
-- C H I M P X 110628 453.53 Testis-expressed sequence 13A protein
CHIMP 1 136911 Tumornecrosis factor receptor superfamilymember 18 precursor
1124826 - HUMAN 1 800938 181.65 Tumor necrosis factor receptor superfamily member 18
precursor
-- C H I M P 1 136911 140 Tumor necrosis factor receptor superfamily member 18
precursor
1124826 - MONK 1 14977 134.83 Tumor necrosis factor receptor superfamily member 18
precursor
- - MONK 1 14977 23.57 Tumor necrosis factor receptor superfamily member 18
precursor
-- C H I M P 1 136911 21.23 Tumor necrosis factor receptor superfamily member 18
precursor
CHIMP 1 178077 Heat-shock proteinbeta-7 (hspb7)
- 16234672 HUMAN 1 816034 160.14 Heat-shock protein beta-7 (hspb7) (Cardiovascular heat
shock protein)
- 16234672 HUMAN 1 816039 160.14 Heat-shock protein beta-7 (hspb7) (Cardiovascular heat
shock protein)
-- C H I M P 1 178077 65.07 Heat-shock protein beta-7 (hspb7) (Cardiovascular heat
shock protein)
CHIMP 1 203439 Eyes absent homolog3(EC 3.1.3.48)
28236481 - MONK 1 19843 67.86 Eyes absent homolog 3 (EC 3.1.3.48)
28236481 - HUMAN 1 870638 67.24 Eyes absent homolog 3 (EC 3.1.3.48)
-- C H I M P 1 203439 58.79 Eyes absent homolog 3 (EC 3.1.3.48)
CHIMP 1 226597 neuroblastomabreakpoint family, member 11 (NBPF11)
114514130 - HUMAN 1 841875 116.78 Neuroblastoma breakpoint family, member 11 (NBPF11)
114514130 - HUMAN 1 842031 116.78 Neuroblastoma breakpoint family, member 11 (NBPF11)
-- C H I M P 1 226597 96.53 Neuroblastoma breakpoint family, member 11 (NBPF11)
-- C H I M P 1 226350 92.54 Neuroblastoma breakpoint family, member 11 (NBPF11)Comparative and Functional Genomics 13
Table 3: Continued.
FR PM Subject Score Function description
CHIMP 1 229134 Tropomyosin alpha-3 chain (Tropomyosin-3)
133314785 - HUMAN 1 843860 241.51 Tropomyosin alpha-3 chain
133314785 - MONK 1 57153 224.17 Tropomyosin alpha-3 chain
-- C H I M P 1 229134 94.16 Tropomyosin alpha-3 chain
CHIMP 1 233220 Voltage-dependent R-typecalcium channel subunitalpha-1E
(Voltage- gated calcium channel subunitalpha Cav2.3)
(Calcium channel, L type, alpha-1 polypeptide, isoform6) (Braincalcium channel II)
161366683 - HUMAN 1 848676 364.5 Voltage-dependent R-type calcium channel subunit
alpha-1E
161366683 - MONK 1 84331 335.27 Voltage-dependent R-type calcium channel subunit
alpha-1E
161366683 - COW 16 164990 306.65 Calcium channel subunit alpha 1E
161366683 - RAT 13 76001 300.14 Voltage-dependent R-type calcium channel subunit
alpha-1E
161366683 - MOUSE 1 2286080 299.66 Calcium channel, Voltage-dependent, R type, alpha 1E
subunit
161366683 - DOG 7 48804 298.94 \N
-- C H I M P 1 233220 149.73 PREDICTED: Pan troglodytes similar to
Voltage-dependent calcium channel alpha-1E-3
CHIMP 1 235105 SOX-13 protein (Type1 diabetes autoantigen ICA12)(Isletcell antigen 12)
184232055 - HUMAN 1 850979 134.55 SOX-13 protein (Type 1 diabetes autoantigen ICA12)
(Islet cell antigen 12)
-- C H I M P 1 235105 55.51 SOX-13 protein (Type 1 diabetes autoantigen ICA12)
(Islet cell antigen 12)
CHIMP X 104156 ADP-ribosylationfactoR-likeprotein 13A
100539703 - HUMAN X 788396 112.96 ADP-ribosylation factoR-like protein 13A
100539703 - HUMAN X 788399 106.14 ADP-ribosylation factoR-like protein 13A
-- C H I M P X 104156 97.94 ADP-ribosylation factoR-like protein 13A
100539703 - MONK X 10115 93 ADP-ribosylation factoR-like protein 13A
HUMAN 1 851772 Complement receptor type1 precursor(c3b/C4b receptor) (CD35 antigen)
-- H U M A N 1 851772 90.18 Complement receptor type 1 precursor (c3b/C4b
receptor) (CD35 antigen)
-- C H I M P 1 235873 86.46 Complement receptor type 1 precursor (c3b/C4b
receptor) (CD35 antigen)
-- C H I M P 1 235895 86.46 Pan troglodytes mrna sequence, 3  end of ORF
205746964 - CHIMP 1 235891 85.81 Complement receptor type 1 precursor (c3b/C4b
receptor) (CD35 antigen)
- - MONK 1 75296 76.91 Complement receptor type 1 precursor (c3b/C4b
receptor) (CD35 antigen)
-- H U M A N 1 851821 75.98 Complement C4b binding protein CR-1 like (Fragment)
205746964 - CHIMP 1 235905 74.1 Pan troglodytes mrna sequence, 3  end of ORF
205746964 - CHIMP 1 235909 74.1 Pan troglodytes mrna sequence, 3  end of ORF
HUMAN 1 851437 solute carrier family 26, member 9 isoformA
204150951 - CHIMP 1 235519 351.23 Solute carrier family 26, member 9 isoform A
204150951 - MONK 1 76747 337.22 Solute carrier family 26, member 9 isoform A
-- H U M A N 1 851439 252.06 Solute carrier family 26, member 9 isoform A14 Comparative and Functional Genomics
Table 3: Continued.
FR PM Subject Score Function description
HUMAN 1 837766 calcium activated chloride channel 3precursor
- 86881166 CHIMP 1 224547 183.12 PREDICTED: Pan troglodytes similar to
calcium—activated chloride channel
--H U M A N 1 837766 157.82 Calcium activated chloride channel 3 precursor
- 86881166 COW 3 170345 139.02 Chloride channel, calcium activated, family member 3
- 86881166 COW 3 170045 138.65 Epithelial chloride channel protein (Calcium—activated
chloride channel)
- 86881166 DOG 6 162589 128.97 \N
- 86881166 MOUSE 3 2282090 123.94 Chloride channel calcium activated 4
- 86881166 RAT 2 220515 118.93 Calcium—activated chloride channel
- 86881166 OPOSSUM 2 28758 118.77 Calcium activated chloride channel 3 precursor
- 86881166 OPOSSUM 2 28690 116.67 Calcium activated chloride channel 3 precursor
- 86881166 RAT 2 220459 114.28 Chloride channel calcium activated 2
- 86881166 MOUSE 3 2281377 114.18 Chloride channel calcium activated 1
- 86881166 MOUSE 3 2281850 110.24 Chloride channel calcium activated 2
- 86881166 COW 3 170620 110.22 Hypothetical protein (Fragment)
- 86881166 RAT 2 220748 109.88 \N
- 86881166 MONK 1 36555 103.72 Calcium activated chloride channel 4
- 86881166 CHIMP 1 224513 103.1 Chloride channel, calcium activated, family member 1
precursor
- 86881166 HUMAN 1 837721 103.1 Chloride channel, calcium activated, family member 1
precursor
- 86881166 MOUSE 3 2282601 102.32 Chloride channel calcium activated 3
- 86881166 MONK 1 36497 102.05 Calcium—activated chloride channel family member 1
- 86881166 COW 3 170508 100.32 Hypothetical protein LOC507504
cell transformation [49]. The gene encoding the testis-
expressed sequence 13A protein is a spermatogonically-
expressed, germ-cell-speciﬁc genetic factor. Cytogenetic
analysis indicated that the gene is located near breakpoints
on the X chromosome in the azoospermic patients with
X-autosome translocations [50] ,s u g g e s t i n gt h a ti tm a yb e
one of the direct genetic risk factors for azoospermia.
Gene of the neuroblastoma breakpoint family, member
11 has been implicated in recent genome duplications,
illegitimate recombination, and chromosomal translocation
in a neuroblastoma patient [51].
Tumor necrosis factor receptor superfamily member 18
precursor (TNFSF18) is a member of the tumor necrosis
factor (TNF) and TNF receptor (TNFR) gene superfamilies.
Data accumulated from experiments indicated that it plays
important roles in regulating cell proliferation, diﬀerentia-
tion, and survival. This was manifested from Gurney’s exper-
iment [52] where cotransfection of the tumor factor receptor
and its ligand in Jurkat T leukemia cells inhibited antigen-
receptor-induced cell death. Recently Kim et al. (2006)
showed the role of the gene in mediating the inﬂammatory
activationofmacrophagesthatcandestabilizeatherosclerotic
plaques [53]. Bae et al., (2008) showed that TNFSF18 may
be involved in the pathogenesis of inﬂammatory diseases
[54]. The stimulation of this gene induced the expression
ofpro-inﬂammatorycytokinesandmatrixmetalloproteinase
(MMP)-9 and up-regulated ICAM-1 expression levels.
Gene of SOX-13 protein is a transcription factor of
the sex-determining region [SRY]-type high mobility group
[HMG] box) family. Among other regulatory functions,
Sox13 is the ﬁrst lineage speciﬁc gene identiﬁed that
modulates T cell lineage development. This gene promotes
gamm/adelta T cell development while opposes alpha/beta T
cell diﬀerentiation [55]. Mice deﬁcient in Sox13 expression
exhibited impaired development of gamma/delta T cells
but not alphabeta T cells. Previous research suggested a
possible role of the heat-shock protein beta-7 (HSPB7) in
cardiovascular development. Krief et al. (1999) found that
it was selectively expressed in cardiovascular and insulin-
sensitive tissues [56]. In obese Zucker rats, its mRNA was
increased in skeletal muscle, brown, and white adipose
tissues but remained unchanged in the heart. Finally, few
data were available for functions of Eya3 except the fact
that the gene is expressed in the developing eye including
the branchial arches and CNS but not cranial placode
[57].Comparative and Functional Genomics 15
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Figure 4: A comparative display of the melanoma-associated gene C3 in humans and chimpanzees: exon-disrupting mutations (I) and
resulting domain structures (II). Note: exons were named in the format of A
B where A is the short abbreviation of mammalian species and
B is the index of the exons. For example, HU
a is the ﬁrst target exon of the human melanoma-associated gene C3 and highlighted by blue,
CM
a-I,C M
a-II,C M
a-III are the three exons derived from HU
a due to the mutations. The neighboring chimpanzee exons were highlighted by
dark and light gray alternatively. The subscript “X” represents nonsense mutation and “!” represents frameshift mutations (a). The cross
represents the truncated part of the protein sequence and MAGE domain (b).
Among these exon-disrupting mutations, those on
protocadherin-11 X-linked precursor (PCDH11X) are espe-
cially inspiring. Single frameshift mutations were detected in
PCDH11X of both chimpanzee and human genomes when
compared to their human Y-linked paralogue (PCDH11Y).
The mutations resulted in the loss of the N-terminal 29-
residue signal peptide in the X-linked protocadherin-11 pro-
teins (Figure 5), suggesting that PCDHY and PCDHX may
function at diﬀerent cellular locations and diﬀerentially reg-
ulated. Indeed, Blanco et al. (2000) observed diﬀerential reg-
ulation in a pluripotential cell line. PCDHX predominated
before retinoic acid treatment whereas PCDHY predomi-
nated after retinoic acid treatment [58]. In addition, Yang
etal.(2005)observedthatthePCDHYisselectivelyexpressed
in apoptosis- and hormone-resistant human prostate cancer
cells [59]. An upgraded expression of PCDHY activated
WNT signaling and drove neuroendocrine transdiﬀeren-
tiation. The observations suggested a signiﬁcant diﬀerent
role of the PCDHY for the process through which prostate
cancers progress to hormone resistance in humans. No Y-
linked protocadherin-11 was observed in the chimpanzee
genome. It will be interesting to investigate the biological
impacts of the lack of the Y-linked protocadherin gene,
structural changes of the melanoma-associated antigens and
many others on physiological properties, especially disease
responses of humans and chimpanzees.
So far, a total of 19 human-speciﬁc, exon-disrupting
mutations were examined and among them, those in
HUMAN 1 851772, HUMAN 1 837766 and HUMAN 1
851437 were validated (Table 3). HUMAN 1 851772 is an
exon for the gene that encodes complement receptor type 1
precursor(C3b/C4b receptor) (CD35 antigen). Thegenewas
identiﬁedastheimmune-adherencereceptorforthecomple-
ment fragments C3b and C4b (CR1) [60]. Its deﬁciency in
erythrocytes was associated with systemic lupus erythemato-
sus [61]. HUMAN 1 851437 is an exon of gene for solute
carrier family 26, member 9 isoform A (SLC26A9). The
analysis of SLC26A9 expression patterns with homeostatic
stress suggested a important role in the mediation of the
response of the airway to stress [62]. HUMAN 1 837766 is16 Comparative and Functional Genomics
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Figure 5: Impacts of exon-disrupting mutations on the structure of the X-linked protocadherin-11 gene in chimpanzees (I) and humans
(II): A frameshift mutation results in the deletion of N-terminal 29-residue signal peptides in the X-linked protocadherin-11 proteins in
chimpanzee and human genomes (III). The dotted box indicates the absence of Y-linked protocadherin-11 in chimpanzees. Signal peptide
was predicted through SignalP 3.0 Server (http://www.cbs.dtu.dk/services/SignalP/)[ 46].
an exon of gene encoding calcium activated chloride channel
3 (CLCA3). As early as 1999, CLCA3 was characterized
as a truncated, secreted member of the human family of
Ca2+-activated Cl−channels [63]. Compared to its 125-kDa
transmembrane paralogous protein, the CLCA3 encodes a
37-kDa glycoprotein that corresponds to the N-terminal
extracellular domain, suggesting that it does not act as a
channel protein but has distinct, yet unidentiﬁed functions.
3.5. Summary. In spite of decades of extensive research,
some questions remains about what is exactly behind the
diﬀerences between two closely-related primates [1]. The
availabilityofcompletelysequencedgenomesofhumansand
chimpanzees allows nucleotide-by-nucleotide comparisons
at whole genome scale. Yet, an immense technique challenge
remains due to the complexities of human and chimpanzee
genomes. With the divide and conquer strategy, ExonVar is
expected to provide new perspective in the ﬁeld. Instead of
comparatively analyzing eukaryotic genes, all the analyses
focused exclusively on exons, the simplest and smallest
coding units in the genomes.
With all the exons on human and chimpanzee genomes,
this analysis demonstrated that the newly developed
pipeline could improve performance and increase accuracy,
and reveal signiﬁcant diﬀerences between humans and
chimpanzees. A large number of species-speciﬁc, exon-
disrupting mutations were revealed in chimpanzees. The
exon-disruptingmutationfracturedexons,truncatedprotein
domains, and thus forced the structural shifts of many
chimpanzee genes away from that of humans. The diﬀer-
entially evolved exons are further involved in many crucial
biological processes such as T cell lineage development,
thepathogenesisof inﬂammatorydiseases, antigen-receptor-
induced cell death, cancer progression and many other
important biological processes. It is thus hypothesized that
the frameshift and nonsense mutations could play a great
role in the human-chimpanzee divergence. Finally, theComparative and Functional Genomics 17
analysis discovered a number of sequencing errors but a
majority of them can be corrected without resequencing.
The pipeline thus will be valuable in improving genome
annotations, enhancing understanding of human evolution,
and eventually, providing drug candidates and strategies for
better disease treatments.
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